Adam Ruth

1.4k total citations
28 papers, 961 citations indexed

About

Adam Ruth is a scholar working on Psychiatry and Mental health, Pharmacology and Experimental and Cognitive Psychology. According to data from OpenAlex, Adam Ruth has authored 28 papers receiving a total of 961 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Psychiatry and Mental health, 14 papers in Pharmacology and 7 papers in Experimental and Cognitive Psychology. Recurrent topics in Adam Ruth's work include Bipolar Disorder and Treatment (17 papers), Treatment of Major Depression (13 papers) and Schizophrenia research and treatment (9 papers). Adam Ruth is often cited by papers focused on Bipolar Disorder and Treatment (17 papers), Treatment of Major Depression (13 papers) and Schizophrenia research and treatment (9 papers). Adam Ruth collaborates with scholars based in United States, Hungary and United Kingdom. Adam Ruth's co-authors include Suresh Durgam, I. Laszlovszky, György Németh, Kaifeng Lu, Anju Starace, Raffaele Migliore, Dayong Li, Stephen R. Zukin, Yao Wang and Krisztián Nagy and has published in prestigious journals such as Journal of Affective Disorders, Schizophrenia Research and The Journal of Clinical Psychiatry.

In The Last Decade

Adam Ruth

28 papers receiving 947 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adam Ruth United States 13 791 275 193 125 121 28 961
B. Szatmári Hungary 11 524 0.7× 131 0.5× 133 0.7× 90 0.7× 119 1.0× 29 658
Meghan M. Grady United States 9 334 0.4× 317 1.2× 137 0.7× 124 1.0× 94 0.8× 16 808
Ágota Barabássy Hungary 14 538 0.7× 127 0.5× 142 0.7× 105 0.8× 128 1.1× 39 720
T. Jacobs United States 9 1.0k 1.3× 374 1.4× 92 0.5× 71 0.6× 155 1.3× 23 1.2k
WFSBP Task Force on Treatment Guide United States 8 1.1k 1.4× 408 1.5× 98 0.5× 190 1.5× 274 2.3× 8 1.4k
S. Corya United States 13 783 1.0× 653 2.4× 103 0.5× 117 0.9× 197 1.6× 26 1.1k
Masaaki Ogasa United States 8 754 1.0× 173 0.6× 190 1.0× 33 0.3× 86 0.7× 18 991
Nicolás A. Núñez United States 14 265 0.3× 138 0.5× 94 0.5× 103 0.8× 117 1.0× 55 711
Meridith A. Rankin United States 6 312 0.4× 196 0.7× 112 0.6× 184 1.5× 185 1.5× 6 673
Jamie Mullen United States 14 1.4k 1.8× 328 1.2× 60 0.3× 55 0.4× 139 1.1× 23 1.7k

Countries citing papers authored by Adam Ruth

Since Specialization
Citations

This map shows the geographic impact of Adam Ruth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Ruth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Ruth more than expected).

Fields of papers citing papers by Adam Ruth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Ruth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Ruth. The network helps show where Adam Ruth may publish in the future.

Co-authorship network of co-authors of Adam Ruth

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Ruth. A scholar is included among the top collaborators of Adam Ruth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Ruth. Adam Ruth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Earley, Willie, Suresh Durgam, Kaifeng Lu, et al.. (2017). Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. Journal of Affective Disorders. 226. 239–244. 29 indexed citations
2.
Khan, Arif, Suresh Durgam, Xiongwen Tang, et al.. (2016). Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone. The Primary Care Companion For CNS Disorders. 18(2). 3 indexed citations
3.
McIntyre, Roger S., Carl Gommoll, Changzheng Chen, & Adam Ruth. (2016). The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials. CNS Spectrums. 21(5). 385–392. 11 indexed citations
4.
Clayton, Anita H., Suresh Durgam, Xiongwen Tang, et al.. (2016). Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies. Neuropsychiatric Disease and Treatment. 12. 1467–1467. 10 indexed citations
5.
Freeman, Marlene P., Maurizio Fava, Carl Gommoll, et al.. (2015). Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder. International Clinical Psychopharmacology. 31(2). 100–109. 8 indexed citations
6.
Durgam, Suresh, Andrew J. Cutler, Kaifeng Lu, et al.. (2015). Cariprazine in Acute Exacerbation of Schizophrenia. The Journal of Clinical Psychiatry. 76(12). e1574–e1582. 137 indexed citations
7.
Kane, John M., Stephen R. Zukin, Yao Wang, et al.. (2015). Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia. Journal of Clinical Psychopharmacology. 35(4). 367–373. 148 indexed citations
8.
Cutler, Andrew J., Carl Gommoll, Changzheng Chen, William M. Greenberg, & Adam Ruth. (2015). Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder. The Primary Care Companion For CNS Disorders. 17(3). 2 indexed citations
9.
Vieta, Eduard, Suresh Durgam, Kaifeng Lu, et al.. (2015). Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials. European Neuropsychopharmacology. 25(11). 1882–1891. 26 indexed citations
10.
Blum, Steven I., Stavros Tourkodimitris, & Adam Ruth. (2014). Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder. Journal of Affective Disorders. 170. 230–236. 13 indexed citations
11.
Durgam, Suresh, Anju Starace, Dayong Li, et al.. (2014). An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. Schizophrenia Research. 152(2-3). 450–457. 147 indexed citations
12.
Perlis, Roy H., William M. Greenberg, Anju Starace, et al.. (2014). Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, Phase III trial. Journal of Affective Disorders. 174. 296–302. 90 indexed citations
13.
Thase, Michael E., Dalei Chen, John Edwards, & Adam Ruth. (2014). Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder. International Clinical Psychopharmacology. 29(6). 351–356. 36 indexed citations
14.
Fava, Maurizio, et al.. (2014). P.2.f.009 The efficacy of levomilnacipran extended-release (ER) in the treatment of patients with depression-associated fatigue symptoms. European Neuropsychopharmacology. 24. S456–S457. 1 indexed citations
15.
Durgam, Suresh, Anju Starace, Raffaele Migliore, et al.. (2014). The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disorders. 17(1). 63–75. 96 indexed citations
16.
Montgomery, Stuart, et al.. (2013). Efficacy and Safety of Levomilnacipran Sustained Release in Moderate to Severe Major Depressive Disorder. The Journal of Clinical Psychiatry. 74(4). 363–369. 61 indexed citations
17.
Montgomery, Stuart, et al.. (2013). The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder. International Clinical Psychopharmacology. 29(1). 26–35. 12 indexed citations
18.
Khan, Arif, Angelo Sambunaris, John Edwards, Adam Ruth, & Donald S. Robinson. (2013). Vilazodone in the treatment of major depressive disorder. International Clinical Psychopharmacology. 29(2). 86–92. 18 indexed citations
19.
Blum, Steven I., Stavros Tourkodimitris, & Adam Ruth. (2012). PMH52 Levomilnacipran in the Treatment of Major Depressive Disorder: Functional Health and Well-Being Efficacy Results from a Phase III Clinical Trial. Value in Health. 15(4). A91–A91. 1 indexed citations
20.
Blum, Steven I., et al.. (2012). P.2.c.022 Levomilnacipran in the treatment of major depressive disorder: functional health and well-being efficacy results from a phase III trial. European Neuropsychopharmacology. 22. S262–S263. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B. Szatmári Breakdown of academic impact, for papers by Meghan M. Grady Breakdown of academic impact, for papers by Ágota Barabássy Breakdown of academic impact, for papers by T. Jacobs Breakdown of academic impact, for papers by WFSBP Task Force on Treatment Guide Breakdown of academic impact, for papers by S. Corya Breakdown of academic impact, for papers by Masaaki Ogasa Breakdown of academic impact, for papers by Nicolás A. Núñez Breakdown of academic impact, for papers by Meridith A. Rankin Breakdown of academic impact, for papers by Jamie Mullen
Rankless by CCL
2026